SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 185 filers reported holding SAGE THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $957,327 | -17.4% | 20,360 | +221.5% | 0.13% | -15.7% |
Q2 2019 | $1,159,000 | -39.3% | 6,332 | -68.2% | 0.16% | +6.0% |
Q4 2018 | $1,908,000 | +271.2% | 19,922 | +447.0% | 0.15% | +150.0% |
Q3 2018 | $514,000 | -35.7% | 3,642 | -28.6% | 0.06% | -40.0% |
Q2 2018 | $799,000 | +0.6% | 5,102 | +3.5% | 0.10% | -3.8% |
Q1 2018 | $794,000 | -25.0% | 4,929 | -23.4% | 0.10% | -25.7% |
Q4 2017 | $1,059,000 | +149.2% | 6,431 | -5.8% | 0.14% | +141.4% |
Q3 2017 | $425,000 | -83.1% | 6,826 | -78.4% | 0.06% | -83.9% |
Q2 2017 | $2,521,000 | +14.9% | 31,660 | +2.5% | 0.36% | +4.9% |
Q1 2017 | $2,194,000 | +268.1% | 30,873 | +164.6% | 0.34% | +251.0% |
Q4 2016 | $596,000 | – | 11,669 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |